6 Ways to Stay Positive While Fighting Cancer
May 5, 2017
A cancer in the family: One spouse’s diagnosis can lower household income
May 8, 2017
Show all

Big Questions Drive Relapsing-Remitting Multiple Sclerosis Research 

Research into relapsing-remitting multiple sclerosis (RRMS) is an important area of MS research.

While treatment for multiple sclerosis (MS) has improved over the past 20 years, there’s still no cure. Most people living with MS have a form of the disease called relapsing-remitting MS (RRMS) with cycles of relapses (when symptoms flare up) followed by periods of remission (times of little or no symptoms). But researchers now better understand the pathways that contribute to MS relapses, and that knowledge is driving the development of new treatments.

During this year’s MS Awareness Month (March), we spoke with Bruce Bebo, Ph.D., executive vice president of Research at the National MS Society, to understand the questions driving MS research today and the progress being made.

The National MS Society is funding more than 300 research projects and invests about $50 million in MS research each year. What are some of the most exciting recent advances?

Advances in repairing the myelin sheath, which protects nerve cells and is destroyed by MS, are encouraging. This approach has tremendous promise to work with immunotherapies to stop the disease from getting worse. MS is an autoimmune disorder in which the body’s immune system attacks and destroys nerve cells; so immunotherapies may ultimately slow down or halt the neurodegeneration in MS. A better understanding of the role of B cells (a type of immune cell) play in this destruction will likely lead to new and improved treatments for this type of MS.

Read full article: Big Questions Drive Relapsing-Remitting Multiple Sclerosis Research – Celgene

Read Full Article: Big Questions Drive Relapsing-Remitting Multiple Sclerosis Research – Celgene

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.